{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 41,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes ASH logo and specific clinical trial metrics (DL levels, AE types).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/29",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.12,
        "x": 0.815,
        "y": 0.145
      },
      "kind": "image",
      "text": "American Society of Hematology logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8ea04c5-8bd4-4323-a453-bde3dd3bd76c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.95,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "list",
      "text": "As of abstract cutoff date: July 10, 2023\n21 patients treated at 5 dose levels with mean 5.8 doses\n8 liquid tumors, 13 solid tumors\n12 evaluable for disease response as of cutoff date\n1 CTCL and 1 PTCL patient at DL2 evaluable with one partial response observed in CTCL patient after two cycles\n10 solid tumors patients (DL1-4) evaluable, with stable disease observed in 3 patients after two cycles at DL3 and DL4\nRobust dose-dependent target knockdown in DL1-4, with DL3 and beyond at levels associated with anti-tumor activity in preclinical models\nMost common AEs were Grade 1 and 2 constipation, fatigue, nausea and anemia\nNo drug related SAEs or DLTs observed; dose escalation ongoing\nFindings support clinical activity with weekly IV infusion\nAdditional data, including other hematological tumor patients, to be presented during poster session at ASH Annual Meeting on December 10",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca71e8d7-79a3-47a1-bdc7-e43824cc52f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.24,
        "y": 0.04
      },
      "kind": "title",
      "text": "KT-333: ASH 2023 Abstract Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7ca8436-57f6-46df-a7df-9297a6e374aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}